U.S. Markets open in 4 hrs 55 mins

JNJ’s Oncology Business Witnessed 45% Growth in Q1 2018

Daniel Collins
JNJ’s Oncology Business Witnessed 45% Growth in Q1 2018

Johnson & Johnson’s (JNJ) Oncology business generated revenues of $2.3 billion in the first quarter compared to $1.6 billion in the first quarter of 2017, reflecting ~45.0% YoY growth. In the US and international markets, Johnson & Johnson’s Oncology business generated first-quarter revenues of $933.0 million and $1.4 billion, respectively. Johnson & Johnson’s Imbruvica reported revenues of $587.0 million in the first quarter compared to $409.0 million in the first quarter of 2017, which reflected ~43.5% YoY growth.